Phase 2Completed
Randomized Study of Obicetrapib as an Adjunct to Statin Therapy (ROSE)
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to High-Intensity Statin Therapy
- Sponsor
- NewAmsterdam Pharma (Industry)
- Enrollment
- 120 enrolled
- Conditions
- Dyslipidemias; High Cholesterol; Hypercholesterolemia
- Interventions
- Obicetrapib
- Ages
- adults, older adults
- Registry
- NCT04753606
Full record on ClinicalTrials.gov
From the registry
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.
Primary outcomes
- Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
- Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
- LS Mean Percent Change Iin Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
- Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]
History
Last registry update
Results first posted
Study completion
Primary completion
Started
Registered